These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10979714)

  • 1. Diabetes and coronary artery disease: time to stop taking the tablets.
    Edwards RJ; Rakhit RD; Marber MS
    Heart; 1999 Jun; 81(6):674. PubMed ID: 10979714
    [No Abstract]   [Full Text] [Related]  

  • 2. Sulfonylureas and the risk of myocardial infarction.
    Thisted H; Johnsen SP; Rungby J
    Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diabetes can even prolong life?].
    Füessl HS
    MMW Fortschr Med; 2014 Oct; 156(17):38. PubMed ID: 25417465
    [No Abstract]   [Full Text] [Related]  

  • 4. Does mortality risk vary among sulfonylureas?
    Pantalone KM
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):6-7. PubMed ID: 25466240
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral sulfonylureas and CV mortality.
    Aronow WS
    Geriatrics; 2004 Sep; 59(9):45-6, 49. PubMed ID: 15461238
    [No Abstract]   [Full Text] [Related]  

  • 6. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Fasching P
    Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk of sulfonylurea drugs is underappreciated.
    Lin WH; Wright JM
    J Am Coll Cardiol; 2000 Mar; 35(3):820-1. PubMed ID: 10716492
    [No Abstract]   [Full Text] [Related]  

  • 8. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
    Meier JJ; Gallwitz B; Schmidt WE; Mügge A; Nauck MA
    Heart; 2004 Jan; 90(1):9-12. PubMed ID: 14676228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide?
    Riddle MC
    J Clin Endocrinol Metab; 2003 Feb; 88(2):528-30. PubMed ID: 12574174
    [No Abstract]   [Full Text] [Related]  

  • 10. Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction.
    Abdelmoneim AS; Welsh RC; Eurich DT; Simpson SH
    Int J Cardiol; 2016 Jan; 202():126-30. PubMed ID: 26386939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfonylurea drugs and cardiovascular mortality.
    O'Keefe JH; McCallister BD; Blackstone EH
    J Am Coll Cardiol; 1999 Sep; 34(3):958. PubMed ID: 10483986
    [No Abstract]   [Full Text] [Related]  

  • 12. Sulfonylureas and mortality in diabetic patients after myocardial infarction.
    Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A
    Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease].
    Nauck MA; Matthaei S
    Dtsch Med Wochenschr; 2005 Apr; 130(17):1091-6. PubMed ID: 15841424
    [No Abstract]   [Full Text] [Related]  

  • 14. A lion in the room: Has the CAROLINA trial definitely resolved the issue of the cardiovascular safety of sulfonylureas?
    Koufakis T; Dimitriadis G; Kotsa K
    J Diabetes; 2020 Jul; 12(7):499-502. PubMed ID: 32202061
    [No Abstract]   [Full Text] [Related]  

  • 15. Diabetes and coronary artery disease: time to stop taking the tablets?
    Connaughton M; Webber J
    Heart; 1998 Aug; 80(2):108-9. PubMed ID: 9813550
    [No Abstract]   [Full Text] [Related]  

  • 16. Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes.
    Barry HC
    Am Fam Physician; 2016 Sep; 94(5):386. PubMed ID: 27583428
    [No Abstract]   [Full Text] [Related]  

  • 17. Impairment of myocardial protection in type 2 diabetic patients.
    Lee TM; Chou TF
    J Clin Endocrinol Metab; 2003 Feb; 88(2):531-7. PubMed ID: 12574175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'.
    Chang Y; Choi NK; Hahn S; Park BJ
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1072-3; author reply 1073-4. PubMed ID: 17907252
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparing cardioprotection by remote ischaemic pre-conditioning in patients with and without diabetes.
    Wang SY; Xue FS; Cui XL
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):768. PubMed ID: 24773561
    [No Abstract]   [Full Text] [Related]  

  • 20. If not sulfonylureas, then what?
    Leibovitch ER
    Geriatrics; 2004 Sep; 59(9):47-8. PubMed ID: 15461239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.